specialty-spotlight-hero
View in browser
 
 
This promotional communication is being provided on behalf of Karyopharm Therapeutics Inc.
 
 
 
NOW
AVAILABLE
The approval of XPOVIO was based upon the efficacy and safety in a prespecified subgroup analysis of the 83 patients whose disease was refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab, as the benefit-risk ratio appeared to be greater in this more heavily pretreated population than in the overall trial population.
Median of 8 prior treatment regimens (range 4, 18)
Median of 7 years since diagnosis (range 1, 23)
 
 
 
 
 
 
Infections
In patients receiving XPOVIO, 52% of patients experienced any grade of infection. Upper respiratory tract infection of any grade occurred in 21%, pneumonia in 13%, and sepsis in 6% of patients. Grade ≥3 infections were reported in 25% of patients, and deaths resulting from an infection occurred in 4% of patients. The most commonly reported Grade ≥3 infections were pneumonia in 9% of patients, followed by sepsis in 6%. The median time to onset was 54 days for pneumonia and 42 days for sepsis. Most infections were not associated with neutropenia and were caused by non-opportunistic organisms.
 
 
 
 
For more information, visit XPOVIO.com
 
 
 
XPOVIO(selinexor) 20mg tablet
 
 
Karyopharm® Therapeutics
XPOVIO is a trademark of Karyopharm Therapeutics. Karyopharm and the logo designs presented in this material are registered trademarks of Karyopharm Therapeutics.
 

This email was sent to amy.gonsuron@iononline.com because you have an account with or are a valued partner of ION Solutions. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.
AmerisourceBergen - 1300 Morris Dr Chesterbrook PA, 19087
© 2019 ION Solutions. All Rights Reserved.